CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
ubenimex +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02664558
NCT02664558Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-BLInd, Placebo- Controlled Study of UBEnimex in Patients With Pulmonary ARTerial HYpertension (WHO Group 1) (LIBERTY)

Eiger BioPharmaceuticals·interventional·Posted Jan 27, 2016·Updated Mar 6, 2023

In Brief

A Phase 2 clinical trial evaluating ubenimex and placebo for Pulmonary Arterial Hypertension. Completed, enrolled 61 participants across 31 sites in 2 countries.

Detailed Summary

This proof-of-concept study is designed as a Phase 2, multicenter, randomized, double-blind, placebo controlled study comparing ubenimex with placebo in patients with pulmonary arterial hypertension (PAH) (World Health Organization \[WHO\] Group 1) and have a WHO/New York Heart Association (NYHA) Functional Classification (WHO/NYHA-FC) of II or III.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 27, 2016
Enrollment StartApr 1, 2016
Primary CompletionNov 1, 2017
Study CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.4 years ago

Interventions

ubenimexdrug

placeboother